Reference : GBA variants in Parkinson’s disease: clinical, metabolomic and multimodal neuroimagin...
Scientific journals : Article
Life sciences : Biotechnology
Life sciences : Multidisciplinary, general & others
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/43780
GBA variants in Parkinson’s disease: clinical, metabolomic and multimodal neuroimaging phenotypes
English
Greuel, Andrea []
Trezzi, Jean-Pierre [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Glaab, Enrico mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Ruppert, Marina C. []
Maier, Franziska []
Jäger, Christian [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Hodak, Zdenka []
Lohmann, Katja []
Yilong, Ma []
Eidelberg, David []
Timmermann, Lars []
Hiller, Karsten []
Tittgemeyer, Marc []
Drzezga, Alexander []
Diederich, Nico []
Eggers, Carsten []
In press
Movement Disorders
John Wiley & Sons
Yes (verified by ORBilu)
International
0885-3185
1531-8257
Hoboken
NY
[en] GBA ; Parkinson's disease ; genetics ; metabolomics ; neuroimaging ; multimodal ; functional ; statistics
[en] Background:
Alterations in the GBA gene (NM_000157.3) are the most important genetic risk factor for Parkinson’s disease. Biallelic GBA mutations cause the lysosomal storage disorder Gaucher´s disease. The GBA variants p.E365K and p.T408M are associated with Parkinson’s but not with Gaucher´s disease. The pathophysiological role of these variants needs to be further explored.

Objective:
This study analyzed the clinical, neuropsychological, metabolic and neuroimaging phenotypes of Parkinson’s disease patients carrying the GBA variants p.E365K and p.T408M.

Methods:
GBA was sequenced in 56 mid-stage Parkinson’s disease patients. Carriers of GBA variants were compared to non-carriers regarding clinical history and symptoms, neuropsychological features, metabolomics and multimodal neuroimaging. Blood plasma gas chromatography coupled to mass spectrometry, [18F]FDopa PET, [18F]FDG PET, and resting-state fMRI were performed.

Results:
Sequence analysis detected 13 heterozygous GBA variant carriers (seven with p.E365K, six with p.T408M). One patient carried a GBA mutation (p.N409S) and was excluded. Clinical history and symptoms were not significantly different between groups. Global cognitive performance was lower in variant carriers. Metabolomic group differences were suggestive of more severe Parkinson’s disease-related alterations in carriers versus non-carriers. [18F]FDopa and [18F]FDG PET showed signs of a more advanced disease; [18F]FDG PET and fMRI showed similarities with Lewy body dementia and Parkinson’s disease dementia in carriers.

Conclusions:
This is the first study to comprehensively assess (neuro-)biological phenotypes of GBA variants in Parkinson’s disease. Metabolomics and neuroimaging detected more significant group differences than clinical and behavioral evaluation. These alterations could be promising to monitor effects of disease-modifying treatments targeting glucocerebrosidase metabolism.
Luxembourg Centre for Systems Biomedicine (LCSB): Biomedical Data Science (Glaab Group)
Fonds National de la Recherche - FnR
FNR11651464 > PD-Strat > Multi-dimensional stratification of Parkinson’s disease patients for personalised interventions > 01/07/2018 > 30/06/2021 > 2018 GLAAB Enrico
Researchers ; Professionals ; Students
http://hdl.handle.net/10993/43780
10.1002/mds.28225
http://dx.doi.org/10.1002/mds.28225
The original publication is available at http://dx.doi.org/10.1002/mds.28225
FnR ; FNR11651464 > Enrico Glaab > PD-Strat > Multi-dimensional stratification of Parkinson’s disease patients for personalised interventions > 01/07/2018 > 30/06/2021 > 2018

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
mds.28225.pdfPublisher postprint1.94 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.